chemokin
demonstr
serv
import
role
varieti
diseas
particularli
tumor
progress
numer
studi
report
cell
serv
major
role
tumor
progress
howev
function
cxc
motif
chemokin
ligand
prostat
cancer
remain
unknown
present
studi
aim
investig
role
prostat
cancer
prostat
cancer
mous
model
gener
treat
mice
dmab
hematoxylin
eosin
stain
detect
histopatholog
alter
mous
prostat
tissu
immunohistochemistri
ihc
stain
determin
cell
prolifer
mice
flow
cytometri
use
detect
alter
cell
mice
immunofluoresc
reveal
posit
express
transform
growth
factor
tgf
mous
tissu
surviv
rate
mice
analyz
associ
express
clinic
stage
also
evalu
result
reveal
prostat
cancer
patholog
cell
prolifer
mice
significantli
greater
compar
mice
compar
mice
number
cell
peripher
blood
spleen
mice
significantli
reduc
ihc
demonstr
express
significantli
downregul
mice
surviv
rate
mice
significantli
decreas
compar
mice
addit
revers
transcriptionquantit
polymeras
chain
reaction
analysi
demonstr
mrna
express
clinic
sampl
posit
associ
clinic
patholog
stage
prostat
cancer
conclus
may
promot
prostat
cancer
progress
via
inhibit
cytokin
cell
st
yg
conceiv
design
experi
st
fs
yl
yg
perform
experi
st
kw
yg
analyz
data
st
kw
fs
yg
contribut
reagentsmaterialsanalysi
tool
st
yg
wrote
manuscript
anim
experi
approv
medic
ethic
committe
linyi
peopl
hospit
tissu
sampl
collect
consent
patient
studi
approv
medic
ethic
committe
linyi
peopl
hospit
prostat
cancer
malign
tumor
occur
prostat
tissu
result
abnorm
dysplasia
prostat
acinar
cell
region
europ
unit
state
prostat
cancer
common
male
malign
mortal
rate
exceed
lung
cancer
incid
prostat
cancer
gradual
increas
arriv
china
age
popul
extens
life
diet
chang
also
known
prostat
cancerassoci
fatal
frequent
occur
patient
metastat
castrationresist
prostat
cancer
although
sever
novel
drug
castrationresist
prostat
cancer
approv
prolong
surviv
month
therefor
novel
treatment
prostat
cancer
requir
extend
life
expect
even
current
immunotherapi
report
effect
treatment
cancer
patient
sever
strate
sever
strate
sever
strategi
includ
cancer
vaccin
immun
checkpoint
inhibitor
investig
clinic
studi
cancer
patient
howev
cell
immunotherapi
prostat
cancer
still
earli
stage
clinic
develop
report
sever
molecul
potent
cell
checkpoint
inhibitor
revers
immunolog
toler
mani
type
cancer
includ
prostat
cancer
therefor
molecul
serv
crucial
role
cell
activ
prostat
cancer
may
use
treatment
diseas
cxc
motif
chemokin
ligand
chemokin
regul
host
respons
inflamm
recruit
leukocyt
inflammatori
environ
chemokin
serv
import
role
immun
respons
bodi
chemokin
express
almost
monocyt
neutrophil
eosinophil
natur
killer
nk
cell
express
lesser
degre
macrophag
b
cell
cell
report
absenc
affect
leukocyt
migrat
tissu
infiltr
abil
interact
varieti
ligand
serv
certain
biolog
role
inflammatori
respons
addit
inflamm
close
associ
occurr
develop
tumor
present
studi
aim
investig
effect
cell
prostat
cancer
clinic
data
prostat
cancer
tissu
specimen
obtain
juli
decemb
linyi
peopl
hospit
linyi
china
patient
age
year
diagnos
prostat
cancer
without
therapi
tissu
sampl
collect
consent
patient
studi
approv
medic
ethic
committe
linyi
peopl
hospit
clinic
stage
patient
clarifi
accord
tumor
node
metastasi
stage
system
adenoma
stage
ii
iii
iv
mice
cell
prostat
cancer
model
black
mice
week
old
male
femal
weight
g
purchas
sun
yatsen
univers
experiment
anim
center
guangzhou
china
use
control
mice
total
four
mice
week
old
male
femal
weight
g
highli
express
purchas
jackson
laboratori
ben
harbor
usa
total
mice
use
studi
maintain
specif
pathogenfre
condit
dark
cycl
humid
normal
diet
includ
fat
cholesterol
water
ad
libitum
dmab
use
chemic
carcinogen
agent
mice
enrol
initi
subcutan
inject
dmab
mgkg
bw
week
week
construct
prostat
cancer
model
mice
anesthet
chloral
hydrat
solut
mlkg
sigmaaldrich
merck
kgaa
darmstadt
germani
blood
sampl
collect
mice
sacrif
cervic
disloc
prostat
tissu
collect
store
anim
experi
approv
medic
ethic
committe
linyi
peopl
hospit
hematoxylineosin
h
e
stain
prostat
tissu
mous
fix
use
formalin
room
temperatur
h
subsequ
tissu
cut
paraffin
section
stain
hematoxylin
min
eosin
sec
room
temperatur
mount
glycerol
solut
distil
water
prevent
autofluoresc
mikrochem
bratislava
slovak
republ
evalu
axiophot
microscop
zeiss
oberkochen
germani
magnif
equip
cellscan
system
scanalyt
bd
bioscienc
franklin
lake
nj
us
immunohistochemistri
immunohistochemistri
perform
accord
convent
protocol
paraffinembed
prostat
tissu
section
incub
dri
oven
h
deparaffin
rehydr
perform
section
incub
antipcna
antibodi
dilut
sigmaaldrich
merck
kgaa
overnight
section
wash
pb
buffer
three
time
time
min
total
hrp
conjug
pcna
secondari
antibodi
beyotim
shanghai
china
ad
tissu
section
incub
h
section
wash
pb
buffer
three
time
time
min
excess
liquid
dri
around
tissu
place
flat
moist
chamber
work
solut
sigmaaldrich
merck
kgaa
ad
section
incub
room
temperatur
min
color
develop
section
rins
distil
water
stop
reaction
posit
result
defin
presenc
stain
cell
stain
tissu
section
review
score
separ
two
pathologist
blind
clinic
paramet
flow
cytometri
blood
sampl
collect
differ
mous
organ
orbit
caviti
ml
caudal
vein
spleen
bone
marrow
red
blood
cell
lysi
buffer
beyotim
institut
biotechnolog
shanghai
china
ad
blood
sampl
centrifug
x
g
min
supernat
discard
bottom
part
precipit
wash
bovin
serum
albumin
bsa
beyotim
institut
biotechnolog
time
room
temperatur
time
min
antibodi
sigmaaldrich
merck
kgaa
ad
dark
incub
min
centrifug
x
g
min
supernat
discard
precipit
wash
time
bsa
supernat
remov
precipit
resuspend
bsa
protein
detect
use
ii
becton
dickinson
franklin
lake
nj
usa
immunofluoresc
stain
prostat
tissu
fix
formaldehyd
min
room
temperatur
wash
time
pb
permeabil
triton
pb
min
also
room
temperatur
paraffinembed
tissu
section
deparaffin
xylen
rehydr
grade
seri
ethanol
solut
incub
min
h
quench
endogen
peroxidas
activ
next
section
heat
target
retriev
solut
dako
agil
technolog
inc
santa
clara
ca
usa
min
microwav
oven
orient
rotor
tokyo
japan
retriev
antigen
subsequ
section
block
bsa
min
beyotim
institut
biotechnolog
incub
primari
antibodi
beyotim
institut
biotechnolog
overnight
stain
fluoresceinconjug
secondari
antibodi
antibodi
antibodi
sigmaaldrich
merck
kgaa
h
room
temperatur
final
imag
captur
leica
aob
confoc
microscop
leica
microsystem
gmbh
wetzlar
germani
number
posit
cell
field
area
ratio
calcul
imag
j
softwar
version
nation
institut
health
bethesda
md
usa
western
blot
tissu
lyse
laemmli
sampl
buffer
biorad
laboratori
inc
hercul
ca
usa
proteas
inhibitor
complet
edtafre
roch
diagnost
gmbh
mannheim
germani
protein
lysat
sampl
extract
tumor
tissu
mice
centrifug
x
g
min
supernat
collect
protein
concentr
measur
use
bca
protein
assay
kit
pierc
thermo
fisher
scientif
inc
waltham
usa
protein
sampl
electrophores
polyacrylamid
gel
biorad
laboratori
transfer
immobilonpsq
polyvinyliden
difluorid
membran
emd
millipor
billerica
usa
membran
block
bsa
min
tb
contain
skim
milk
incub
antibodi
sigmaaldrich
merck
kgaa
overnight
final
membran
incub
hrp
conjug
secondari
antibodi
beyotim
institut
biotechnolog
room
temperatur
min
protein
visual
use
enhanc
chemiluminesc
reagent
biorad
laboratori
inc
hercul
ca
usa
protein
semiquantifi
use
imag
j
softwar
version
nation
institut
health
revers
transcriptionquantit
polymeras
chain
reaction
rtqpcr
total
rna
extract
prostat
tissu
patient
use
trizol
reagent
invitrogen
thermo
fisher
scientif
inc
revers
transcript
perform
random
primer
use
first
strand
cdna
synthesi
kit
takara
biotechnolog
co
ltd
dalian
china
rtqpcr
perform
sybrgreen
pcr
master
mix
thermo
fisher
scientif
inc
pcr
cycl
run
icycl
iq
multicolor
detect
system
biorad
laboratori
inc
cycl
condit
sec
cycl
sec
sec
cycl
primer
use
amplif
f
gtc
ggc
tgt
tcc
tgc
r
aca
tct
gct
gaa
tct
ggg
ttt
gapdh
f
ccg
tca
agg
ctg
aga
r
tga
aga
cgc
cag
tgg
rel
express
level
calcul
use
method
gapdh
employ
endogen
control
data
analysi
perform
base
sampl
threshold
cycl
ct
valu
three
independ
experi
statist
analysi
data
analyz
use
spss
version
statist
softwar
ibm
corp
armonk
ny
usa
result
immunohistochemistri
analyz
imag
pro
plu
softwar
version
media
cybernet
inc
rockvil
md
usa
p
consid
indic
statist
signific
differ
oneway
analysi
varianc
conduct
follow
bonferroni
method
post
hoc
test
multipl
comparison
kaplanmei
surviv
plot
gener
comparison
construct
logrank
statist
p
consid
indic
statist
signific
differ
high
express
gene
promot
pathogenesi
prostat
cancer
mice
order
determin
whether
overexpress
affect
pathogenesi
prostat
cancer
mice
prostat
cancer
induc
mice
h
e
stain
fig
reveal
prostat
cancer
patholog
mice
significantli
greater
mice
mice
develop
differenti
adenocarcinoma
week
nuclear
stain
significantli
greater
duct
irregular
glandular
caviti
becam
smaller
black
arrow
week
mice
exhibit
clear
patholog
prostat
cancer
neuroendocrin
differenti
phenotyp
fig
therefor
mice
week
select
subsequ
experi
immunohistochem
stain
magnif
prolifer
cell
nuclear
antigen
pcna
reveal
prolifer
level
mice
increas
compar
mice
fig
aforement
result
suggest
overexpress
serv
import
role
promot
progress
prostat
cancer
acceler
pathogenesi
prostat
cancer
high
express
inhibit
cell
activ
chemokin
serv
import
role
tumor
microenviron
hypothes
regul
cellmedi
immun
present
studi
examin
alter
cell
peripher
blood
spleen
mice
mice
result
show
reduct
number
cell
peripher
blood
spleen
mice
compar
mice
fig
quadrant
infiltr
number
cell
tumor
tissu
also
examin
mice
mice
result
suggest
high
express
significantli
inhibit
cell
infiltr
tumor
microenviron
fig
base
find
hypothes
may
regul
order
verifi
whether
overexpress
affect
cytokin
secret
tumor
microenviron
express
level
prostat
tissu
examin
result
demonstr
high
express
downregul
level
tumor
tissu
compar
mice
fig
b
therefor
conclud
reduc
secret
via
reduct
number
cell
immun
organ
tumor
microenviron
promot
develop
prostat
cancer
high
express
acceler
pathogenesi
prostat
cancer
address
associ
overexpress
progress
prostat
cancer
surviv
rate
mice
mice
measur
result
suggest
surviv
rate
mice
lower
mice
fig
addit
mrna
express
level
clinic
sampl
measur
mrna
level
patient
stage
iii
greater
stage
ii
mrna
level
patient
stage
iv
greater
stage
iii
result
suggest
mrna
express
level
posit
associ
clinic
stage
fig
prostat
cancer
highli
malign
tumor
complex
pathogenesi
abnorm
express
level
chemokin
identifi
prostat
cancer
mani
chemokin
may
inhibitori
effect
tumor
certain
chemokin
may
promot
tumor
progress
sever
chemokin
includ
use
translat
medicin
previou
studi
associ
cancer
demonstr
howev
effect
prostat
cancer
report
previou
studi
reveal
highli
express
human
digest
organ
gastrointestin
organ
howev
express
development
organ
studi
present
studi
mice
mice
select
investig
chemic
induct
use
induc
prostat
cancer
mice
demonstr
may
serv
import
role
promot
tumorigenesi
addit
effect
inhibit
knockdown
gene
tumorigenesi
import
fulli
illustr
effect
howev
limit
present
studi
experi
perform
due
difficulti
gene
knockout
mous
construct
howev
investig
studi
underli
mechan
promot
pathogenesi
prostat
cancer
investig
present
studi
chemokin
serv
import
role
tumor
microenviron
hypothes
serv
indirect
role
affect
white
blood
cell
result
suggest
cell
spleen
signifi
cell
spleen
signifi
cell
spleen
significantli
reduc
mice
previou
studi
report
regul
home
lymphocyt
thymu
affect
cell
matur
tumor
mous
model
function
regul
cell
matur
reduc
number
cell
requir
investigacel
requir
investigacel
requir
investig
produc
activ
cell
antitumor
effect
antitumor
biolog
activ
primarili
includ
promot
prolifer
kill
activ
nk
promot
nk
cell
secret
interferon
express
receptor
agonist
chain
ii
induc
lymphoinduc
lymphoinduc
lymphocyteactiv
killer
cell
may
dissolv
varieti
tumor
cell
present
studi
demonstr
reduc
present
studi
demonstr
reduc
present
studi
demonstr
reduct
number
cell
peripher
blood
spleen
mice
compar
mice
cytokin
secret
immun
cell
abil
inhibit
tumor
cell
growth
induc
tumor
degener
studi
reveal
antitumor
effect
depend
secret
helper
cdposit
cell
inhibit
tumor
growth
angiogenesi
receptorinteract
serinethreonin
protein
kinas
rip
model
mice
mous
model
rip
promot
may
control
obtain
hybrid
model
mice
lmcv
mice
demonstr
cell
serv
import
role
inhibit
tumor
growth
present
studi
conclud
cell
express
level
reduc
increas
level
result
enhanc
growth
tumor
hybrid
mice
overexpress
reduc
number
cell
immun
organ
tumor
microenviron
reduc
secret
therebi
promot
develop
prostat
cancer
wa
ob
e
r
h
h
e
su
r
v
iva
l
r
e
mice
significantli
reduc
compar
mice
therefor
target
inhibit
express
may
appli
clinic
set
rtqpcr
detect
mrna
express
prostat
cancer
patient
differ
patholog
stage
result
reveal
mrna
express
level
posit
associ
clinic
stage
clinic
sampl
suggest
patient
high
express
exhibit
advanc
patholog
featur
conclus
present
studi
suggest
express
prostat
cancer
associ
clinic
stage
may
inhibit
express
prostat
cancer
model
mice
howev
underli
regulatori
mechan
develop
prostat
cancer
requir
investig
